XML 33 R23.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Development, Commercialization and Supply Agreements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Summary of Product Approval | The Company received approval of VASCEPA under the MARINE and REDUCE-IT indications in the following countries:
Country |  | MARINE |  | REDUCE-IT |  |  | Launch Date |
Lebanon |  | March 2018 |  | August 2021 |  |  | June 2018 |
United Arab Emirates |  | July 2018 |  | October 2021 |  |  | February 2019 |
Qatar |  | December 2019 |  | April 2021 |  |  |  | — |
Bahrain |  | April 2021 |  | April 2022 |  |  |  | — |
Kuwait |  | December 2021 |  |  | — |  |  |  | — |
Saudi Arabia |  | March 2022 |  |  | — |  |  |  | — |
Changes in Balances of Contract Assets and Liabilities and Revenues Recognized | The following table presents changes in the balances of the Company’s contract assets and liabilities during the nine months ended September 30, 2022 and 2021:
In thousands | Balance at Beginning of Period |  |  | Additions |  |  | Deductions |  |  | Balance at End of Period |
Nine months ended September 30, 2022: |  |  |  |  |  |  |  |  |  |  |
Contract assets | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Contract liabilities: |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | $ | 16,709 |  |  | $ | — |  |  | $ | (1,012 | ) |  | $ | 15,697 |
Nine months ended September 30, 2021: |  |  |  |  |  |  |  |  |  |  |
Contract assets | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Contract liabilities: |  |  |  |  |  |  |  |  |  |  |
Deferred revenue | $ | 18,632 |  |  | $ | 92 |  |  | $ | (1,592 | ) |  | $ | 17,132 |
During the nine months ended September 30, 2022 and 2021, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods:
In thousands | Nine months ended September 30, |
Revenue recognized in the period from: | 2022 |  |  | 2021 |
Amounts included in contract liability at the beginning of the period | $ | 1,012 |  |  | $ | 1,555 |
Performance obligations satisfied in previous periods | $ | — |  |  | $ | 33 |

X
- Definition Summary of product approval. + References No definition available. + Details
Name: | amrn_SummaryOfProductApprovalTableTextBlock
Namespace Prefix: | amrn_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration